Giuseppe Curigliano, MD, PhD, is the director of the Early Drug Development Division and holds the co-chair for Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milano, Italy. He is a steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milano. Moreover, he is a member of the Italian National Health Council, serving as advisor of the Ministry of Health for cancer policy issues.

He worked at the Columbia University Comprehensive Cancer Center in New York, USA, developing experience in preclinical and translational research. He was also a visiting scholar at the Dana Farber Cancer Institute, Harvard Medical School in Boston, USA. At the European Institute of Oncology, he served as Co-Director of the Division of Medical Oncology until 2014.

Professor Curigliano obtained his medical and specialist degree from the Catholic University in Rome, Italy. He is a specialist in Medical Oncology. He obtained a PhD in Clinical Pharmacology at the University of Pisa, Italy.

Professor Curigliano served as an expert panel member issuing the AIOM, ESMO, and ASCO guidelines in breast cancer and germline gene testing recommendations. He co-chaired for several years the scientific committee of the St Gallen Early Breast Cancer Conference. He is also a scientific board member of EUSOMA (European Society of Breast Cancer Specialists). He is serving as a member of the Scientific Board of the International Breast Cancer Study Group (IBCSG). He is serving on the executive board of the Breast International Group (BIG).

Professor Curigliano is the principal investigator and steering committee member of numerous breast and early development clinical trials, particularly with innovative targeted compounds and individualized treatment strategies. His translational research focusses on the field of biomarkers and personalised therapies, biomarker discovery, development of targeted agents, and implementation of personalised medicine. His team includes 40 people (including medical staff, research nurse, oncology nurse, and medical oncology residents) working on basic sciences, bioinformatics, biotechnologies, and clinical research. He is also leading phase I-III trials testing targeted agents in the field of breast cancer, agnostic and large national trials testing the implementation of high-throughput technologies in the health care system.

He has a strong interest in artificial intelligence and established in the University of Milano the first Master's in Artificial Intelligence in Cancer Medicine.